Cimetidine IV — Competitive Intelligence Brief

Cimetidine IV (Cimetidine IV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H2-receptor antagonist. Area: Gastroenterology.

phase 3 H2-receptor antagonist Histamine H2 receptor Gastroenterology Small molecule

Target snapshot

Cimetidine IV (Cimetidine IV) — Bausch Health Americas, Inc.. Cimetidine is a histamine H2-receptor antagonist that reduces gastric acid secretion by blocking histamine-mediated stimulation of parietal cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cimetidine IV TARGET	Cimetidine IV	Bausch Health Americas, Inc.	phase 3	H2-receptor antagonist	Histamine H2 receptor
Axid Ar	NIZATIDINE		marketed	Histamine-2 Receptor Antagonist [EPC]	Histamine H2 receptor	1988-01-01
Zantac	ranitidine	GSK (originally Glaxo)	marketed	H2 receptor antagonist	Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor	1983-06-01
Histalog	BETAZOLE		marketed	betazole	Histamine H2 receptor	1982-01-01
Tagamet	CIMETIDINE		marketed	Histamine-2 Receptor Antagonist [EPC]	Histamine H2 receptor	1977-01-01
Bentyl	dicycloverine	Forest Labs Inc	marketed	Anticholinergic	Histamine H2 receptor	1950-01-01
Rosuvastatin-ranitidine	Rosuvastatin-ranitidine	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist	HMG-CoA reductase (rosuvastatin component); Histamine H2 receptor (ranitidine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H2-receptor antagonist class)

1. Bausch Health Americas, Inc. · 1 drug in this class
2. Bristol-Myers Squibb · 1 drug in this class